Phase 1/2Recruiting
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (KYANITE-1)
KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs
- Sponsor
- Krystal Biotech, Inc. (Industry)
- Enrollment
- 250 planned
- Conditions
- Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancer (NSCLC)
- Interventions
- KB707; Pembrolizumab (KEYTRUDA®); Chemotherapy; Docetaxel
- Ages
- adults, older adults
- Registry
- NCT06228326
Full record on ClinicalTrials.gov
From the registry
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for…
Primary outcomes
- To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Model projects the most cytotoxic breast cancer chemotherapy costs 9.4 life-years through accelerated aging
The Georgetown-led simulation compared regimens in women ages 30–79 using blood p16 as an aging marker; JAMA Network Open published the findings.
Also in GEN (opens GEN in a new tab), Infobae (opens Infobae in a new tab), BES.media (opens BES.media in a new tab), xeu.mx (opens xeu.mx in a new tab)
